Clinical trial
Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00088556 is registered in ClinicalTrials.gov with Telik as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Telik
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- May 31, 2009
- Enrollment
- 100 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.